Age-Related Macular Degeneration and the Risk of Depression, Anxiety, and Mood Disorders: What We Know, Why It Matters, and How to Act

Executive Summary

• Mood disorders are common in AMD. Across observational studies, depressive symptoms range roughly 16%–44%, and anxiety symptoms 10%–30%, with higher rates in clinical/late-stage populations (1).

• Incident risk: Large population cohorts suggest AMD diagnosis increases the risk of new-onset depression, especially when visual disability is present (2). Not all cohorts agree, highlighting heterogeneity in measurement and case mix (12).

• Mechanisms include functional vision loss → activity restriction, social isolation, fear of blindness, chronic inflammation/oxidative stress, and shared geriatric vulnerabilities (1,3,25–27).

• Screening with PHQ-9 (depression) and GAD-7 (anxiety) is practical and validated in medical settings (30–32). The HADS is commonly used in ophthalmic research and clinics (33–36).

• Effective interventions:

  • Low-vision rehabilitation (LVR) + behavioral activation/problem-solving therapy prevents depressive disorders and reduces symptoms in AMD (3,28,29).

  • Collaborative care models for late-life depression improve outcomes and can be embedded in ophthalmology/primary care interfaces (4,11,37–39).

  • Standard antidepressant therapies (SSRIs/SNRIs) plus CBT/BA/PST are evidence-based in older adults; coordinate with vision-specific rehab.

• Care pathway: Normalize screening at diagnosis and major vision milestones, refer for LVR, initiate brief psychotherapy, and coordinate with primary care/psychiatry as needed.

---

1) Epidemiology: How Common Are Depression and Anxiety in AMD?

Point prevalence & symptom burden

A systematic review of observational studies in AMD reported depression 15.7%–44% and anxiety 9.6%–30.1%, with higher burden at greater disease severity (1). Large clinic-based series and community cohorts consistently show worse visual acuity and activity loss correlate with higher depressive symptom scores (1,25–27).

Incident (new-onset) mood disorders after AMD diagnosis

A nationwide cohort showed AMD and AMD-related visual disability were associated with increased subsequent risk of depression, even after adjustment for sociodemographic and clinical factors (2). Other cohorts found elevated probabilities of mood disorders following AMD (9), while at least one population cohort reported no significant association when controlling broadly for confounders (12). Differences likely reflect population mix, AMD phenotyping, outcome definitions, and follow-up.

Subgroups

Advanced subtypes (e.g., geographic atrophy and neovascular AMD) are frequently associated with greater depressive symptom severity, driven by central scotomas, reading difficulty, and loss of independence (13,26–27).

---

2) Why AMD and Mood Disorders Are Linked: Mechanisms

1. Vision loss → activity limitation → social isolation
   AMD impairs reading, face recognition, driving, and daily living, which reduces autonomy and increases isolation—direct pathways to depression and anxiety (1,25–27).

2. Fear of blindness & uncertainty
   Intermittent exacerbations (e.g., fluid recurrence) sustain anticipatory anxiety and health uncertainty, known precipitants of anxiety disorders in chronic disease (1,26–27).

3. Inflammation/oxidative stress
   AMD pathology involves oxidative stress and chronic inflammation, biological pathways also implicated in depression pathophysiology in late life (1).

4. Geriatric multimorbidity
   Co-existing hearing loss, frailty, cardiovascular disease, and polypharmacy can amplify psychological stress and symptom expression (25–27).

5. Personality & resilience moderators
   Traits such as neuroticism have predicted depression severity in AMD; coping style, social support, and self-efficacy moderate risk (26–27).

---

3) Clinical Consequences

• Quality of life declines across mobility, social participation, and role functioning, with visual disability and depressive symptoms each independently reducing QoL (1,25–27).

• Adherence risk: Depression can impair adherence to intravitreal injection schedules and self-care, risking worse visual outcomes over time (26–27).

• Safety & falls: Anxiety and depression are associated with falls risk, compounding the functional impact of low vision (25–27).

---

4) Screening: Practical Tools and When to Use Them

Instruments

• PHQ-9 (9 items): valid for diagnosis/severity; ≥10 suggests clinically significant depression (30,34–36).

• GAD-7 (7 items): validated for generalized anxiety; ≥10 suggests clinically significant anxiety (31–32).

• HADS (14 items): widely used in medical clinics; 8–10 often used as a case-finding threshold on subscales (33–36).

Timing & workflow

• At AMD diagnosis and at major vision milestones (new exudation, GA expansion affecting fixation, driving cessation).

• During LVR enrollment and post-treatment follow-ups (e.g., every 3–6 months in the first year).

• Positive screen → brief risk assessment (suicidality), warm handoff to primary care or behavioral health, and initiate LVR + brief psychotherapy where available.

---

5) What Works: Treatment & Counseling Recommendations

5.1 Low-Vision Rehabilitation (LVR) + Behavioral Interventions

• Randomized clinical trial evidence shows Behavioral Activation (BA) + LVR prevents onset of depressive disorders and reduces symptoms compared with supportive therapy + LVR in AMD patients with subsyndromal depression (3,28–29).

• Problem-Solving Therapy (PST) tailored to vision loss improves function and mood by targeting goal setting, compensatory strategies, and re-engagement in valued activities (14,21,28–29).

• Rationale: These activation-focused psychotherapies directly counter avoidance and withdrawal that follow vision loss.

5.2 Collaborative Care (stepped care) for Late-Life Depression

• The IMPACT model and subsequent trials demonstrate superiority over usual care for depressive symptoms and remission in older adults, integrating care managers, psychiatric consultation, and measurement-based care (4,11,22,37–39).

• How to use it in AMD: Embed PHQ-9/GAD-7 monitoring, introduce brief psychotherapies (BA/CBT/PST), and coordinate medication management with PCP/psychiatry.

5.3 Antidepressant Pharmacotherapy

• SSRIs/SNRIs are effective in late-life depression; choose agents with favorable side-effect profiles for older adults (orthostasis, hyponatremia) and review ocular meds for interactions. Combine with behavioral therapyand LVR for functional gains (11,37–39).

5.4 Vision-Directed Care and Quality of Life

• Timely anti-VEGF therapy stabilizes or improves vision in neovascular AMD; mood may improve secondarily as reading/functional vision stabilizes, though mood symptoms can persist without targeted treatment (26).

• Assistive technology (magnification, contrast enhancement, e-readers), environmental modifications (lighting, high-contrast cues), and mobility training reduce disability and anxiety, supporting recovery of activity (1,25–27).

5.5 Counseling & Self-Management

• Psychoeducation: Normalize the prevalence of mood symptoms; explain treatability and the role of activation.

• Lifestyle: Encourage regular physical activity, sleep regularity, smoking cessation, social connection, and nutritional adequacy (antioxidants, omega-3s) consistent with overall ocular health (1,25–27).

• Family/Carer involvement: Teach supportive behaviors that facilitate autonomy rather than overprotection, and watch for mood changes.

---

6) A Practical Care Pathway for Clinics

1. Screen (PHQ-9, GAD-7; HADS acceptable) at diagnosis and major milestones.

2. Stratify:

   • Mild symptoms (PHQ-9 5–9 / GAD-7 5–9): education + LVR referral + BA-informed self-help; recheck in 4–6 weeks.

   • Moderate-severe (≥10): collaborative care referral, consider CBT/BA/PST, and pharmacotherapy if persistent/impairing.

   • Any suicidality → urgent risk assessment and mental-health referral.

3. Treat & monitor: Measurement-based care (PHQ-9/GAD-7 monthly initially), adjust modality/intensity.

4. Maintain: After improvement, schedule booster visits, reinforce activation and vision strategies, and rescreen at vision status changes.

---

7) Areas of Ongoing Debate & Research Needs

• Causality vs correlation: While several cohorts show elevated incident depression risk after AMD, others report null associations after broad adjustment (2,12).

• Phenotype specificity: Clarify which AMD subtypes (e.g., GA vs neovascular) confer greatest psychiatric risk (13).

• Implementation: Pragmatic trials embedding collaborative care + LVR + BA/PST within ophthalmology and retina practices are needed to define scalable models (22,37–39).

---

8) Key Takeaways for Patients and Families

• Mood symptoms in AMD are common and treatable.

• Ask your care team for PHQ-9/GAD-7 screening and a low-vision rehabilitation referral.

• Behavioral activation and problem-solving help you re-enter valued activities despite vision changes.

• Depression and anxiety are not a sign of weakness; they’re predictable responses to life-changing vision loss—and there are effective treatments.

---

References 

1. Dawson SR, et al. The prevalence of anxiety and depression in people with age-related macular degeneration: a systematic review of observational study data. Clin Ophthalmol. 2014;8:1179–91. PMC

2. Hwang S, et al. Impact of age-related macular degeneration and related visual disability on the risk of depression: a nationwide cohort study. Ophthalmology. 2023;130(6):615–23. PubMed+1

3. Rovner BW, et al. Low Vision Depression Prevention Trial in age-related macular degeneration: randomized clinical trial of behavioral activation plus low-vision rehabilitation. Ophthalmology. 2014;121(11):2204–11. PMC+2PubMed+2

4. Unützer J, et al. Collaborative care management of late-life depression in the primary care setting (IMPACT). JAMA. 2002;288(22):2836–45. JAMA Network

5. Lee CY, et al. Increased probability of mood disorders after age-related macular degeneration: a nationwide cohort. Sci Rep. 2022;12:15262. Nature

6. Rezapour J, et al. Prevalence and new onset of depression and anxiety in a population-based cohort with and without AMD. Sci Rep. 2020;10:8435. Nature

7. Brody BL, et al. Depression, visual acuity, comorbidity, and disability associated with AMD. Ophthalmology.2001;108(10):1893–1900. PMC

8. Mathew RS, et al. Depressive symptoms and quality of life in people with AMD. Ophthalmic Physiol Opt.2011;31(4):375–80. PMC

9. Wysong A, et al. Longitudinal incidence of adverse outcomes of AMD. Arch Ophthalmol. 2009;127(3):320–7. PMC

10. Augustin A, et al. Anxiety and depression prevalence rates in AMD. Invest Ophthalmol Vis Sci.2007;48(4):1498–503. PMC

11. Gilbody S, et al. Collaborative care for subthreshold depression in older adults: randomized trial. JAMA.2017;317(7):728–37. JAMA Network

12. Tran E, et al. Prevalence of anxiety and depression symptoms in AMD: meta-analytic estimates. Arch Med Health Sci. 2025;13(1):xx–xx. Lippincott Journals

13. Faia LJ, et al. Comorbid depression and anxiety risk in geographic atrophy. Ophthalmol Ther. 2025;xx:xx–xx. PMC

14. Rovner BW, et al. Problem-Solving Therapy vs Supportive Therapy in low vision. Clin Geriatr Med/Rehab (trial reports/abstracts). 2011. ScienceDirect

15. Casten R, Rovner BW, et al. Depression despite anti-VEGF treatment of AMD. Arch Ophthalmol. 2010;128:506–8. PMC

16. Mitchell J, Bradley C. Quality of life in AMD: review. Health Qual Life Outcomes. 2006;4:97. PMC

17. Slakter JS, Stur M. QoL in AMD and treatment benefits. Surv Ophthalmol. 2005;50(3):263–73. PMC

18. Popescu ML, et al. Explaining the relationship between eye disease and depressive symptoms in older adults. Invest Ophthalmol Vis Sci. 2012;53(4):2308–13. PMC

19. Sun C, et al. Depressive symptoms and AMD in older people (Cardiovascular Health Study). Ophthalmic Epidemiol. 2007;14(3):127–33. PMC

20. Rovner BW, Casten RJ. Activity loss and depression in AMD. Am J Geriatr Psychiatry. 2002;10(3):305–10. PMC

21. Sörensen S, et al. Preventive Problem-Solving Therapy for AMD (MADAS trial). CDC HHS Report. 2015. CDC Stacks

22. Björkelund C, et al. Collaborative care with care managers: pragmatic cluster RCT. BMC Prim Care. 2018;19:83. BioMed Central

23. Stewart JC, et al. Timing of depression treatment and cardiometabolic risk (context for collaborative care). Gen Hosp Psychiatry. 2023;81:25–33. PubMed

24. Smith JD, et al. Collaborative care rollout effectiveness-implementation trial. Gen Hosp Psychiatry. 2021;69:1–9. ScienceDirect

25. Dawson SR, et al. Mechanisms linking vision loss and mood symptoms in AMD (review discussion). Clin Ophthalmol. 2014;8:1179–91. PMC

26. Casten RJ, Rovner BW, et al. Neuroticism, disability, and depression in AMD. J Am Geriatr Soc.2001;49(8):1097–1100; and related works. PMC

27. Brody BL, et al. Disability and depression in AMD. Ophthalmology. 2001;108(10):1893–1901. PMC

28. ClinicalTrials.gov. Low Vision Depression Prevention Trial (VITAL). NCT00769015. ClinicalTrials

29. Rovner BW, et al. Low-vision depression prevention (trial report, Ophthalmology 2014). Ophthalmology.2014;121:2204–11. PMC

30. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–13. PubMed

31. Spitzer RL, et al. A brief measure for assessing generalized anxiety disorder (GAD-7). Arch Intern Med.2006;166:1092–7. PubMed+1

32. Rutter LA, et al. Psychometric properties of the GAD-7. Assessment. 2017;24(1):1–10. PMC

33. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale (HADS). Acta Psychiatr Scand.1983;67:361–70. PubMed

34. APA. PHQ-9 overview and performance metrics. Practice resources. 2016. APA

35. Medscape Reference. PHQ-9 calculator overview. 2024. Medscape Reference

36. Sun Y, et al. Reliability and validity of PHQ-9 in medical populations. BMC Psychiatry. 2020;20:291. PMC

37. Unützer J, et al. IMPACT intervention details. JAMA. 2002;288(22):2836–45. PubMed

38. Smith JD, et al. Hybrid rollout of collaborative care. Gen Hosp Psychiatry. 2021;69:1–9. ScienceDirect

39. Gilbody S, et al. Collaborative care trial in older adults with subthreshold depression. JAMA. 2017;317(7):728–37.